NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis $0.44 +0.02 (+4.25%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.45 +0.01 (+2.26%) As of 10/9/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Moleculin Biotech Stock (NASDAQ:MBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Moleculin Biotech alerts:Sign Up Key Stats Today's Range$0.41▼$0.4650-Day Range$0.39▼$0.8352-Week Range$0.16▼$15.75Volume341,015 shsAverage Volume1.24 million shsMarket Capitalization$8.61 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research programs are based on compounds designed to target biological mechanisms involved in tumor growth, drug resistance and immune-system regulation. The company’s lead program is annamycins, including L-annamycin, an anthracycline designed to retain anticancer activity while reducing some limitations associated with conventional anthracyclines, particularly damage to the heart. Moleculin has studied annamycin in clinical programs for acute myeloid leukemia and soft-tissue sarcoma. Its broader oncology pipeline has included WP1066, a STAT3 pathway inhibitor being investigated for cancers such as glioblastoma, and related compounds targeting oncogenic signaling pathways. Moleculin is headquartered in Houston, Texas, and its development activities have included clinical research in the United States and international locations. Walter Klemp has served as the company’s chairman and chief executive officer. As a clinical-stage biotechnology company, Moleculin’s programs remain subject to clinical, regulatory and commercial development risks.AI Generated. May Contain Errors. Read More Moleculin Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreMBRX MarketRank™: Moleculin Biotech scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMoleculin Biotech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMoleculin Biotech has a consensus price target of $3.00, representing about 578.7% upside from its current price of $0.44.Amount of Analyst CoverageMoleculin Biotech has only been the subject of 2 research reports in the past 90 days.Read more about Moleculin Biotech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($2.37) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Moleculin Biotech is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Moleculin Biotech is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Moleculin Biotech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 28.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentMoleculin Biotech has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Moleculin Biotech this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MBRX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows2 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders18.04% of the stock of Moleculin Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of Moleculin Biotech is held by institutions.Read more about Moleculin Biotech's insider trading history. Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBRX Stock News HeadlinesMoleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitOctober 7 at 8:45 AM | globenewswire.comMoleculin Biotech Updates Investors With New PresentationOctober 5, 2026 | tipranks.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.October 10 at 1:00 AM | Base Camp Trading (Ad)Analysts Are Bullish on These NA Stocks: Moleculin Biotech (MBRX), Alphabet Class A (GOOGL)October 2, 2026 | theglobeandmail.comMoleculin Completes Part A Enrollment In Phase 2/3 MIRACLE Trial For Relapsed AMLSeptember 29, 2026 | rttnews.comMoleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data ReadoutSeptember 29, 2026 | globenewswire.comMoleculin Reports Cardiac Safety Findings For Annamycin In Pooled AnalysisSeptember 28, 2026 | rttnews.comMoleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineSeptember 28, 2026 | finance.yahoo.comSee More Headlines MBRX Stock Analysis - Frequently Asked Questions How have MBRX shares performed this year? Moleculin Biotech's stock was trading at $3.31 at the start of the year. Since then, MBRX shares have decreased by 86.6% and is now trading at $0.4420. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($1.40) earnings per share for the quarter, topping analysts' consensus estimates of ($1.55) by $0.15. When did Moleculin Biotech's stock split? Shares of Moleculin Biotech reverse split on the morning of Monday, December 1st 2025.The 1-25 reverse split was announced on Wednesday, November 26th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Moleculin Biotech IPO? Moleculin Biotech (MBRX) raised $8 million in an IPO on Thursday, June 2nd 2016. The company issued 1,540,026 shares at a price of $5.00-$6.00 per share. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Company Calendar Last Earnings8/13/2026Today10/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MBRX's financial health is in the Green zone, according to TradeSmith. MBRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MBRX CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees17Year Founded2006Price Target and Rating Average Price Target for Moleculin Biotech$3.00 High Price Target$3.00 Low Price Target$3.00 Potential Upside/Downside+578.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($7.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-143.51% Return on Assets-24.53% Debt Debt-to-Equity RatioN/A Current Ratio0.94 Quick Ratio0.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book0.09Miscellaneous Outstanding Shares19,480,000Free Float15,963,000Market Cap$8.61 million OptionableNot Optionable Beta2.00 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MBRX) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
